analytica InnovationArea: Start-ups in the Spotlight

23-26 March 2010, Munich, Germany.
Following its successful premiere in 2008, analytica, the leading trade fair for industrial analysis, laboratory technology and biotechnology, will continue its initiative for new companies again in 2010. International start-ups and research organizations in the biotechnology sector will present their business ideas and document the importance of the life sciences in a special area known as the InnovationArea. Lectures and panel discussions at the Biotech Forum, which is located in the immediate vicinity of the InnovationArea, will give visitors additional insights into the trends and innovative strength of this industry.

The fact that research and development are heavily influenced by the innovative strength of new, smaller companies is well-known in the life-sciences sector. Each year the biotech industry grows by several dozen new companies. The research results of these start-ups and research institutes give the industry direction and important impetus. "The InnovationArea expands the scope of the traditional exhibition sectors at analytica to include an important, fundamental branch of industry, i.e. research and development. It gives new companies and research institutes in this sector a perfect platform for presenting their innovations, products, services, research results and business ideas to a broad-based domestic and international audience. It also gives them an opportunity to make new contacts and cultivate existing ones - and at attractive rates," says Thomas Rehbein, Exhibition Director of analytica, explaining the concept of the special exhibition sector.

However, the InnovationArea is more than just a cluster of exhibits. Its close physical proximity to the Biotech Forum and the fact that the themes of both platforms are closely related is intended to promote dialog. On all four days of the fair, the presentation stage will feature discussions and presentations about future technologies and research trends in the life sciences. The most important topics include industrial biotechnology and personalized healthcare, and Finance Day on Friday will examine ways to financially support new research organizations and start-ups.

The InnovationArea was an immediate success when it celebrated its premiere in 2008. The compact platform featured new biotech and life-science companies as well as start-ups in the nano-chemistry, micro-reaction technology and bioinformatics sectors. The fact that it got off to such as successful start is also reflected by the ratings that the InnovationArea received. Eighty percent of all exhibitors gave the new attraction a rating of good to excellent - ratings that it received by an impressive 85 percent of all visitors.

The basic perquisites for participating in the InnovationArea as well as all relevant facts and figures and an application form are available online at www.analytica.de/link/en/innovationarea.

About analytica
analytica, which includes the Analytica Conference, is the leading European trade fair for analysis, laboratory technology, biotechnology/life sciences, diagnostics and data and process management. It is held in Munich, the leading trade-fair venue and business location in the world. Visitors include decision-makers and users from the chemical, medical and pharmaceutical sectors as well as industrial and government research organizations. Analytica is held every two years and has established itself as a central marketplace for marketable products and solutions as well as innovations. The 22nd analytica is being held at the New Munich Trade Fair Centre from March 23-26, 2010.

analytica is part of an international network of trade fairs: It includes the trade fairs analytica, analytica China (Shanghai, Sept. 15-17, 2010), analytica Anacon India (Fall 2011) and analytica Vietnam (April 7-9, 2011). Additional information about the fair(s) and the program of events is available on the Internet at www.analytica.de.

Messe München International (MMI)
Messe München International (MMI) is one of the world's leading trade-fair companies. It organises around 40 trade fairs for capital and consumer goods, and key high-tech industries. Each year over 30,000 exhibitors from more than 100 countries, and over two million visitors from more than 200 countries take part in the events in Munich. In addition, MMI organises trade fairs in Asia, Russia, the Middle East and South America. With six subsidiaries abroad - in Europe and in Asia - and with 64 foreign representatives serving 89 countries, MMI has a truly global network. Via its six subsidiaries - in Europe and in Asia - and 64 foreign representatives actively serving over 90 countries, MMI has a worldwide business network. Environmental protection and sustainability are key priorities in all MMI's operations, at home and abroad.

Further information: www.messe-muenchen.de.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...